Pirfenidone Patent Expiration
Pirfenidone is used for treating idiopathic pulmonary fibrosis. It was first introduced by Legacy Pharma Inc Sezc
Pirfenidone Patents
Given below is the list of patents protecting Pirfenidone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Esbriet | US10188637 | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same | Mar 28, 2037 | Legacy |
| Esbriet | US8778947 | Methods of administering pirfenidone therapy | Aug 30, 2033 | Legacy |
| Esbriet | US7816383 | Methods of administering pirfenidone therapy | Jan 08, 2030 | Legacy |
| Esbriet | US7910610 | Methods of administering pirfenidone therapy | Jan 08, 2030 | Legacy |
| Esbriet | US8013002 | Methods of administering pirfenidone therapy | Jan 08, 2030 | Legacy |
| Esbriet | US8084475 | Pirfenidone therapy and inducers of cytochrome P450 | Jan 08, 2030 | Legacy |
| Esbriet | US8318780 | Methods of administering pirfenidone therapy | Jan 08, 2030 | Legacy |
| Esbriet | US8648098 | Pirfenidone therapy and inducers of cytochrome P450 | Jan 08, 2030 | Legacy |
| Esbriet | US8754109 | Pirfenidone therapy and inducers of cytochrome P450 | Jan 08, 2030 | Legacy |
| Esbriet | US7566729 | Modifying pirfenidone treatment for patients with atypical liver function | Apr 22, 2029 | Legacy |
| Esbriet | US7635707 | Pirfenidone treatment for patients with atypical liver function | Apr 22, 2029 | Legacy |
| Esbriet | US8592462 | Pirfenidone treatment for patients with atypical liver function | Apr 22, 2029 | Legacy |
| Esbriet | US8609701 | Pirfenidone treatment for patients with atypical liver function | Apr 22, 2029 | Legacy |
| Esbriet | US8383150 | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients | May 10, 2028 | Legacy |
| Esbriet | US7696236 | Method of providing pirfenidone therapy to a patient | Dec 18, 2027 | Legacy |
| Esbriet | US7696326 | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof | Dec 18, 2027 | Legacy |
| Esbriet | US7767700 | Method of providing pirfenidone therapy to a patient | Dec 18, 2027 | Legacy |
| Esbriet | US8420674 | Method of providing pirfenidone therapy to a patient | Dec 18, 2027 | Legacy |
| Esbriet | US7767225 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep 22, 2026
(Expired) | Legacy |
| Esbriet | US7988994 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep 22, 2026
(Expired) | Legacy |
| Esbriet | US8753679 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep 22, 2026
(Expired) | Legacy |
| Esbriet | US9561217 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan 25, 2022
(Expired) | Legacy |
Pirfenidone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pirfenidone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
